XML 24 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenues:        
Total revenues $ 20,617 $ 57,203 $ 41,534 $ 115,132
Costs and expenses:        
Cost of sales (excluding amortization of intangible assets) 5,238 2,124 6,637 4,699
Research and development expenses 1,626 1,263 2,667 3,056
Selling, general and administrative expenses 28,131 24,755 55,445 49,800
Amortization of intangible assets 4,855 25,443 12,650 50,887
Restructuring charges 6,519 0 6,519 0
Total costs and expenses 46,369 53,585 83,918 108,442
(Loss) income from operations (25,752) 3,618 (42,384) 6,690
Other income (expense):        
Loss on extinguishment of convertible notes (16,272) 0 (47,880) 0
Interest expense (1,604) (14,842) (10,278) (31,396)
Loss on prepayment of Senior Notes 0 0 (8,233) 0
Other loss (499) (1,240) (3,824) (1,849)
Total other (expense) income (18,219) (16,082) 41,691 (33,245)
Net loss before income taxes (43,971) (12,464) (693) (26,555)
Income tax benefit (expense) 9,472 (1,141) 7,424 (1,351)
Net (loss) income (34,499) (13,605) 6,731 (27,906)
Comprehensive (loss) income $ (34,499) $ (13,605) $ 6,731 $ (27,906)
Basic net (loss) income per share (in dollars per share) $ (0.35) $ (0.21) $ 0.07 $ (0.43)
Diluted net (loss) income per share (in dollars per share) $ (0.35) $ (0.21) $ 0.07 $ (0.43)
Shares used in computing basic net (loss) income per share (in shares) 98,558 64,480 89,835 64,405
Shares used in computing diluted net (loss) income per share (in shares) 98,558 64,480 90,236 64,405
Product sales, net        
Revenues:        
Total revenues $ 20,165 $ 25,937 $ 29,417 $ 52,387
Commercialization agreement, net        
Revenues:        
Total revenues 0 31,003 11,258 61,859
Royalties and milestones        
Revenues:        
Total revenues 452 263 859 886
Gralise        
Revenues:        
Total revenues (116) 17,800 431 31,078
Other income (expense):        
Loss (Gain) on sale of assets (850) 0 126,655 0
NUCYNTA        
Other income (expense):        
Loss (Gain) on sale of assets $ 1,006 $ 0 $ (14,749) $ 0